Amylyx Pharmaceuticals Reports $45.5M Third-Quarter Loss
Story updates
12:09:24 PM UTC
SquawkNews
Amylyx Pharmaceuticals 3Q Loss/Shr 38c >AMLX
Related stories
Verisk Analytics reports third-quarter revenue of $809 million
M impact | EQUITY | Nov 05, 2026, 12:22 PM UTC
Evolent Health Reports Third-Quarter Revenue of $725.37 Million
Revenue rose 51.3% year over year as the net loss narrowed. Growth reflected Performance Suite contract go-lives and expanded oncology services, partly offset by lower membership a
M impact | EQUITY | Nov 05, 2026, 12:19 PM UTC
Evergy Reports Q3 Operating Revenue of $2.1B
Evergy's Q3 operating revenue was $2.1 billion, compared with a FactSet estimate of $1.93 billion.
M impact | EQUITY | Nov 05, 2026, 12:15 PM UTC
Climb Bio Reports Third-Quarter Loss of $14.6 Million
M impact | EQUITY | Nov 05, 2026, 12:15 PM UTC
ConocoPhillips Reports Q3 Revenue and Other Income of $20.06B
ConocoPhillips posted Q3 total revenue and other income of $20.06 billion, compared with a FactSet estimate of $18.59 billion.
M impact | EQUITY | Nov 05, 2026, 12:15 PM UTC
Verisk Reports Third-Quarter 2026 Results
Revenue was $809 million, up 5.3% year over year and 7.4% on an organic constant-currency basis.
M impact | EQUITY | Nov 05, 2026, 12:15 PM UTC